Metric Finance
LearnFAQ
LearnFAQ

Learn / BLCO

NYSE: BLCO

Bausch & Lomb (BLCO) stock, explained like you're 5

Bausch & Lomb trades on the New York Stock Exchange under the ticker BLCO. It is a mid cap company in the ophthalmic goods industry, part of the healthcare sector, with a market value of about 6.2 billion dollars.

Ticker
BLCO
Exchange
New York Stock Exchange
Sector
Healthcare
Industry
Ophthalmic Goods
Size
Mid cap, about 6.2 billion dollars

Is Bausch & Lomb a small, medium or large cap company?

No. Bausch & Lomb is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 6.2 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Bausch & Lomb makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves BLCO stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • BLCO Stock Drops After Hours Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure (Stocktwits)
  • 3 Reasons BLCO is Risky and 1 Stock to Buy Instead (Yahoo Finance)
  • $BLCO stock is down 8% today. Here's what we see in our data. (Quiver Quantitative)
  • Why Is Bausch + Lomb Stock Falling Monday? Bausch Health Companies (NYSE:BHC), Bausch & Lomb (NYSE:BLCO (Benzinga)
  • Bausch & Lomb: Sudden Leadership Transition Raises Questions, but We Hold Valuation Steady (Morningstar)

Follow BLCO in your daily brief

Each trading day at 5 PM ET we post what happened to Bausch & Lomb and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow BLCO

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Bausch & Lomb stock

What does Bausch & Lomb do?

Bausch & Lomb trades on the New York Stock Exchange under the ticker BLCO. It is a mid cap company in the ophthalmic goods industry, part of the healthcare sector, with a market value of about 6.2 billion dollars.

What is the ticker symbol for Bausch & Lomb?

Bausch & Lomb trades under the ticker BLCO on the New York Stock Exchange.

What is Bausch & Lomb's market cap?

Bausch & Lomb is a mid cap stock with a market cap of about 6.2 billion dollars.

How does Bausch & Lomb make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves BLCO stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow BLCO stock every day?

Add BLCO to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow BLCO daily

A free brief on Bausch & Lomb and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ALC · Alcon
  • COO · Cooper Companies
  • WRBY · Warby Parker
  • EYE · National Vision Holdings

Similar stocks

  • ALCAlcon
  • COOCooper Companies
  • WRBYWarby Parker
  • EYENational Vision Holdings

Compare BLCO: BLCO vs ALC, BLCO vs COO, BLCO vs WRBY

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed